Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Fiche publication
Date publication
janvier 2021
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle
Tous les auteurs :
Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C
Lien Pubmed
Résumé
The use of antibiotics (ATB) and proton-pump inhibitors (PPI) alters the composition and diversity of the gut microbiota, which can influence the immune system, consequently interfering with response to anti-PD1 immune checkpoint inhibitors (ICI). We assessed the impact of ATB and/or PPI use on the efficacy and safety of ICI.
Mots clés
antibiotics, head and neck cancer, immune checkpoint inhibitors (ICI), melanoma, non-small cell lung cancer (NSCLC), non-small-cell lung carcinoma (NSCLC), proton-pump inhibitor (PPI), renal cell carcinoma (RCC)
Référence
Front Immunol. 2021 ;12:716317